AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy ... Read More